Highlights Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:03 2025-05-16 EDT			5-day change	1st Jan Change
91.47 ^CHF	+1.25%		+0.62%	+3.12%

05-16	STOXX 600 rounds off fifth week of gains, Cartier-parent Richemont advances	RE
05-16	STOXX 600 rounds off fifth week of gains, Cartier-parent Richemont advances	RE

Highlights

Novartis: new data at ASCO and EHA	05-15	CF
Trump's Mandate for Lower Drug Prices Threatens Roche's Plans for US Investments	05-14	MT
Incyte to Pay Novartis $280 Million to Resolve Jakafi Royalties Dispute	05-14	MT
GSK Strikes up to $2 Billion Deal to Acquire Boston Pharmaceuticals' Liver Disease Drug Candidate	05-14	MT
Novartis Signs MoU for Disease Awareness, Prevention Campaigns in Abu Dhabi	05-14	MT
GSK to buy liver disease drug for up to $2 billion	05-14	RE
GSK to Buy Boston Pharmaceuticals' Potential Liver Medicine for Up to $2 Billion	05-14	MT
Novo Nordisk latest drugmaker to drop gender goals in US	05-07	RE
BioNTech Maintains Full-Year Revenue Outlook Despite Surprise Quarterly Sales Decline	05-05	MT
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge	05-01	RE
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge	05-01	RE
Sector Update: Health Care Stocks Rise Wednesday Afternoon	04-30	MT
Top Midday Gainers	04-30	MT
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal	04-30	RE
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal	04-30	RE
Top Midday Stories: Nvidia, Oracle Rush Chip Shipments Ahead of Export Rule; Super Micro Cuts Fiscal Q3 EPS, Net Sales Guidance	04-30	MT
Regulus Shares Surge on $1.7 Billion Acquisition by Novartis	04-30	DJ
Novartis: agreement reached to acquire Regulus Therapeutics	04-30	CF
Novartis to Acquire Regulus in $1.7 Billion Deal	04-30	DJ
Novartis to Buy Regulus Therapeutics for Up to $1.7 Billion	04-30	MT
Novartis to Acquire Regulus Therapeutics	04-30	MT
Novartis to Acquire Regulus Therapeutics	04-30	MT
Regulus Therapeutics Enters Into Agreement To Be Acquired By Novartis AG	04-30	RE
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure	04-30	DJ
Novartis to buy Regulus Therapeutics for up to $1.7 billion	04-30	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

NOVARTIS : Q1 ahead of expectations; outlook revised higher

April 29, 2025 at 07:58 am

Novartis CEO Says They Will Have to 'Tackle Rhetoric' in US Healthcare

January 21, 2025 at 03:33 pm

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am